Cargando…

Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies

Gene therapy is a revolutionary, cutting-edge approach to permanently ameliorate or amend many neuromuscular diseases by targeting their genetic origins. Motor neuron diseases and muscular dystrophies, whose genetic causes are well known, are the frontiers of this research revolution. Several geneti...

Descripción completa

Detalles Bibliográficos
Autores principales: Chamakioti, Myrsini, Karantzelis, Nikolaos, Taraviras, Stavros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101723/
https://www.ncbi.nlm.nih.gov/pubmed/35563214
http://dx.doi.org/10.3390/ijms23094824
_version_ 1784707157183168512
author Chamakioti, Myrsini
Karantzelis, Nikolaos
Taraviras, Stavros
author_facet Chamakioti, Myrsini
Karantzelis, Nikolaos
Taraviras, Stavros
author_sort Chamakioti, Myrsini
collection PubMed
description Gene therapy is a revolutionary, cutting-edge approach to permanently ameliorate or amend many neuromuscular diseases by targeting their genetic origins. Motor neuron diseases and muscular dystrophies, whose genetic causes are well known, are the frontiers of this research revolution. Several genetic treatments, with diverse mechanisms of action and delivery methods, have been approved during the past decade and have demonstrated remarkable results. However, despite the high number of genetic treatments studied preclinically, those that have been advanced to clinical trials are significantly fewer. The most clinically advanced treatments include adeno-associated virus gene replacement therapy, antisense oligonucleotides, and RNA interference. This review provides a comprehensive overview of the advanced gene therapies for motor neuron diseases (i.e., amyotrophic lateral sclerosis and spinal muscular atrophy) and muscular dystrophies (i.e., Duchenne muscular dystrophy, limb-girdle muscular dystrophy, and myotonic dystrophy) tested in clinical trials. Emphasis has been placed on those methods that are a few steps away from their authoritative approval.
format Online
Article
Text
id pubmed-9101723
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91017232022-05-14 Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies Chamakioti, Myrsini Karantzelis, Nikolaos Taraviras, Stavros Int J Mol Sci Review Gene therapy is a revolutionary, cutting-edge approach to permanently ameliorate or amend many neuromuscular diseases by targeting their genetic origins. Motor neuron diseases and muscular dystrophies, whose genetic causes are well known, are the frontiers of this research revolution. Several genetic treatments, with diverse mechanisms of action and delivery methods, have been approved during the past decade and have demonstrated remarkable results. However, despite the high number of genetic treatments studied preclinically, those that have been advanced to clinical trials are significantly fewer. The most clinically advanced treatments include adeno-associated virus gene replacement therapy, antisense oligonucleotides, and RNA interference. This review provides a comprehensive overview of the advanced gene therapies for motor neuron diseases (i.e., amyotrophic lateral sclerosis and spinal muscular atrophy) and muscular dystrophies (i.e., Duchenne muscular dystrophy, limb-girdle muscular dystrophy, and myotonic dystrophy) tested in clinical trials. Emphasis has been placed on those methods that are a few steps away from their authoritative approval. MDPI 2022-04-27 /pmc/articles/PMC9101723/ /pubmed/35563214 http://dx.doi.org/10.3390/ijms23094824 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chamakioti, Myrsini
Karantzelis, Nikolaos
Taraviras, Stavros
Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies
title Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies
title_full Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies
title_fullStr Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies
title_full_unstemmed Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies
title_short Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies
title_sort advanced gene-targeting therapies for motor neuron diseases and muscular dystrophies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101723/
https://www.ncbi.nlm.nih.gov/pubmed/35563214
http://dx.doi.org/10.3390/ijms23094824
work_keys_str_mv AT chamakiotimyrsini advancedgenetargetingtherapiesformotorneurondiseasesandmusculardystrophies
AT karantzelisnikolaos advancedgenetargetingtherapiesformotorneurondiseasesandmusculardystrophies
AT taravirasstavros advancedgenetargetingtherapiesformotorneurondiseasesandmusculardystrophies